The following presentation titled ‘Pharma Patents and Drug Prices’ was delivered by Dr. Kalyan C. Kankanala (Managing Partner, BananaIP Counsels, Bangalore) on 5th January, 2016 at the conference on “Affordability, Accessibility and Availability of Medicine and IPR” at National Law School of India University. Organized through the Centre for Intellectual Property Rights Research and Advocacy and MHRD Chair on Intellectual Property Rights, the conference was held at the International Training Centre, NLSIU, Bengaluru.
The following topics were covered as a…
Chapter VI of the Patent Rules, 2003 deals with Opposition proceedings. Rule 55 states that opposition by representation against the grant of a patent be duly field via Form 7 and sent to the Controller in duplicate. Rule 57 lays down rule regarding filing of a written statement of opposition and evidence.
By the Patents (Amendment) Act, 2005 a dichotomy was inserted for the first time in the Patents Act with effect from January 1, 2005 by providing for “opposition…